Gimpo, South Korea
Gimpo, South Korea

Time filter

Source Type

The present invention relates to a novel Bifidobacterium strain having an excellent growth promoting effect, and a nutraceutical composition for promotion of growth, which contains the strain. The strain of the present invention has a beneficial effect of promoting growth by promoting the digestion of human milk oligosaccharides to enhance immunity together with physical strength.


The present invention a Bi fidobacterium longum CBT BG7 Bifidobacterium, which has an excellent growth promoting effect and was internationally deposited with the Korean Collection for Type Culture (KCTC) of the Korea Research Institute of Bioscience and Biotechnology under accession number KCTC 12200BP. The strain of the present invention has a beneficial effect of promoting growth by promoting the digestion of human milk oligosaccharides to enhance immunity together with physical strength.


Lee S.J.,Dongguk University | Bose S.,Dongguk University | Seo J.-G.,Cell Biotech Co. | Chung W.-S.,Cell Biotech Co. | And 2 more authors.
Clinical Nutrition | Year: 2014

Background & aims: Probiotics help maintain balance in composition of the gut microbiota, and have been considered as a potential treatment for obesity. This study was conducted in order to assess the effects of probiotics when combined with herbal medicine in treatment of obesity. Probiotics were tested for the ability to modulate gut microbiota, gut permeability, and endotoxin level, which may have correlation with factors involved in obesity. Methods: A randomized, double-blind, placebo controlled study was conducted, in which patients with higher BMI (>25 kg/m2) and waist circumference (>85cm) were enrolled and randomly assigned to receive Bofutsushosan with either probiotics or placebo capsules for a period of eight weeks. Assessment of body composition parameters, metabolic biomarkers, endotoxin level, gut permeability, and fecal bacteria in stool was performed at baseline and at week 8. The study was registered at the Clinical Research Information Service, approved by the Korea National Institute of Health (KCT0000386). Results: Although both groups showed a significant reduction in weight and waist circumference (p=0.000), no significant differences in body composition and metabolic markers were observed. In correlation analysis, change in body composition showed positive correlation with endotoxin level (r=0.441, p<0.05 for BW; and r=0.350, p<0.05 for fat mass) and the population of gut Lactobacillus plantarum (r=0.425, p<0.05 for BW; and r=0.407, p<0.05 for BMI). The Gram negative bacterial population in gut also exhibited positive correlation with changes in body composition (WC) and total cholesterol level (r=0.359, and 0.393, for the former and later parameters, respectively, p<0.05 for both). While, the profile of gut Bifidobacterium breve population showed negative correlation with endotoxin level (r=-0.350, p<0.05). Conclusions: Correlations between gut microbiota and change in body composition indicate that probiotics may influence energy metabolism in obesity. Correlation between endotoxin level and weight reduction indicates that probiotics may play an important role in prevention of endotoxin production, which can lead to gut microbiota dysbiosis associated with obesity. © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.


Nam Y.-D.,Kyung Hee University | Nam Y.-D.,Korea Food Research Institute | Kim H.J.,Seoul National University | Seo J.-G.,Cell Biotech Co Ltd | And 2 more authors.
PLoS ONE | Year: 2013

Although pelvic irradiation is effective for the treatment of various cancer types, many patients who receive radiotherapy experience serious complications. Gut microbial dysbiosis was hypothesized to be related to the occurrence of radiation-induced complications in cancer patients. Given the lack of clinical or experimental data on the impact of radiation on gut microbiota, a prospective observational study of gut microbiota was performed in gynecological cancer patients receiving pelvic radiotherapy. In the current study, the overall composition and alteration of gut microbiota in cancer patients receiving radiation were investigated by 454 pyrosequencing. Gut microbial composition showed significant differences (P < 0.001) between cancer patients and healthy individuals. The numbers of species-level taxa were severely reduced after radiotherapy (P < 0.045), and the abundance of each community largely changed. In particular, the phyla Firmicutes and Fusobacterium were significantly decreased by 10% and increased by 3% after radiation therapy, respectively. In addition, overall gut microbial composition was gradually remolded after the full treatment course of pelvic radiotherapy. In this set of cancer patients, dysbiosis of the gut microbiota was linked to health status, and the gut microbiota was influenced by pelvic radiotherapy. Although further studies are needed to elucidate the relationship between dysbiosis and complications induced by pelvic radiotherapy, the current study may offer insights into the treatment of cancer patients suffering from complications after radiation therapy. Copyright: © 2013 Nam et al.


Trademark
Cell Biotech Co. | Date: 2012-11-21

Baby food made from livestock products; baby foods made from agricultural products; lacteal flour for babies; medicine for intestinal disorders; medicines for veterinary purposes namely, for treatment of intestinal bacteria; agents for immunity adjustment; milk ferments for pharmaceutical purposes; medicines for alleviating constipation; additives to fodder for medical purposes in the nature of dietary supplements; nutritional supplements for medical purposes; chewing gum for medical purposes; lactic acid bacteria capsules for medical purposes; lactic acid bacteria microorganisms for medical purposes; biological preparations for medical purposes for treatment of cancer, heart disease, and neurological diseases; all of the foregoing containing probiotics. Lactic acid bacteria drinks; lactic-acid fermented milk; yogurt; nutritional supplement containing lactic ferments; lactic-acid fermented cheese; lactic-acid fermented sausages; ham containing lactic ferments; lactic-acid fermented kimchi; all of the foregoing containing probiotics. Brown rice flour for food; frozen yogurt namely, confectionery ices; chewing gum; candy; mayonnaise; dressings for salad; ginseng tea; black tea; green tea; coffee-based beverages; lactic-acid fermented bread; all of the foregoing containing probiotics.


Trademark
Cell Biotech Co. | Date: 2013-09-25

Baby food made from livestock products; Baby food made from agricultural products; Lacteal flour for babies; Medicine for intestinal disorders; Medicines for veterinary purposes; Pharmaceutical preparations for immunity adjustment; Milk ferments for pharmaceutical purposes; Veterinary preparations; Medicines for alleviating constipation; Additives to fodder for medical purposes; Dietetic substances adapted for medical use; Nutritional supplements for medical purposes; Chewing gum for medical purposes; Antidiarrheal; Lactic acid bacteria capsules for medical purposes; Lactic acid bacteria microorganisms for medical purposes; Biological preparations for medical purposes; Nutritive substances for microorganisms; Nutritive substances for microorganisms for medical use; Preparations of microorganisms for medical and veterinary use. Lactic acid bacteria drinks; Fermented milk; Yoghurt; Health functional foods whose main ingredient is lactic acid bacteria; Lactic acid bacteria fermented cheese; Lactic acid bacteria fermented sausages; Ham containing lactic acid bacteria; Lactic acid bacteria fermented Kimchi; Vegetable products processed; Food products made from fruit; Foods prepared from bean curds (tofu); Bean processed foodstuffs excluding bean curds and their processed foodstuffs; Meat; Processed egg foodstuffs; Meat products processed; Processed dairy products; Food products made from oil and fat; Seaweed products processed; Food products made from fish and shellfish; Food products made from worm.


Trademark
Cell Biotech Co. | Date: 2015-07-22

Baby food made from livestock products; baby food made from agricultural products; lacteal flour for babies; medicine for intestinal disorders; medicine for veterinary purposes namely, for treatment of intestinal bacteria; agents for immunity adjustment; milk ferments for pharmaceutical purposes; medicines for alleviating constipation; additives to fodder for medical purposes in the nature of dietary supplements; nutritional supplements for medical purposes; chewing gum for medical purposes; lactic acid bacteria capsules for medical purposes; lactic acid bacteria microorganisms for medical purposes; biological preparations for medical purposes for treatment of cancer, heart disease, and neurological diseases; all of the foregoing containing probiotics; nutritional supplement containing lactic ferments. Lactic acid bacteria drinks; lactic-acid fermented milk; yogurt; lactic-acid fermented cheese; lactic-acid fermented sausages; ham containing lactic ferments; lactic-acid fermented kimchi; all of the foregoing containing probiotics. Brown rice flour for food; frozen yogurt namely, confectionery ices; chewing gum; candy; mayonnaise; dressings for salad; ginseng tea; black tea; green tea; coffee-based beverages; lactic-acid fermented bread; all of the foregoing containing probiotics.


Patent
Cell Biotech Co. and Chung | Date: 2013-10-09

The present invention relates to an antibacterial material comprising a tyndallized dead lactic acid bacteria lyophilizate and a dried tyndallized fermented filtrate prepared by a process comprising the steps of tyndallizing a fermented broth of lactic acid bacteria and then separating the tyndallized fermented broth into a tyndallized fermented filtrate and a tyndallized dead lactic acid bacteria-containing solution; freeze-drying the tyndallized dead lactic acid bacteria-containing solution so as to form a tyndallized dead lactic acid bacteria lyophilizate; fluidized-bed-drying or freeze-drying the tyndallized fermented filtrate so as to from a dried tyndallized fermented filtrate; and mixing the tyndallized dead lactic acid bacteria lyophilizate and the dried tyndallized fermented filtrate, and a preparing method thereof. The antibacterial material comprising the tyndallized dead lactic acid bacteria lyophilizate, according to the present invention, may have a homogeneous appearance and an excellent antibacterial activity, and thus may be appropriately used to prepare various medicines, foods, feeds, and cosmetics which require antibacterial activity and intestinal regulation.


Patent
Cell Biotech Co. | Date: 2011-10-11

The present invention relates to multi-coated lactic acid bacteria coated with a multi-coating layer forming bacterial clusters and including protein, polysaccharide, and edible oil/fat component, and a preparing method thereof. The multi-coated lactic acid bacteria according to the present invention may achieve an improved acid resistance, a bile resistance, and an accelerated test stability, may have a low moisture content to be particularly stable against a moisture variation, and thus may be appropriately used to prepare various products including lactic acid bacteria.


The present invention relates to multi-coated lactic acid bacteria coated with a multi-coating layer forming bacterial clusters and including protein, polysaccharide, and edible oil/fat component, and a preparing method thereof. The multi-coated lactic acid bacteria according to the present invention may achieve an improved acid resistance, a bile resistance, and an accelerated test stability, may have a low moisture content to be particularly stable against a moisture variation, and thus may be appropriately used to prepare various products including lactic acid bacteria.

Loading Cellbiotech Co. collaborators
Loading Cellbiotech Co. collaborators